Disarming bacteria to defeat resistant infections

This article is in partnership with:

Rory Triniman

PhD, CEO, Veirulence Ltd

Antibiotics are no longer adequate as the only treatment option for bacterial infections. Virulence factor targeting therapies could be a solution to the medical and commercial challenges that antibiotics are unable to address.


Pseudomonas aeruginosa is a World Health Organization (WHO) priority pathogen, associated with severe hospital-acquired infections with high levels of antimicrobial resistance (AMR). Rory Triniman, CEO of Veirulence Ltd, believes the answer lies in looking beyond antibiotics. “The question has long been: how can we kill bacteria?” says Triniman. “What we should be asking is how bacteria cause infection.”

Virulence factor targeting therapies

Virulence factors are characteristics or mechanisms that enable a microorganism, such as a bacterium or fungus, to cause infection and disease in a host. “These are the weapon systems bacteria use to cause disease,” explains Triniman. “Targeting these mechanisms, rather than killing the bacteria directly, disarms pathogens while reducing the evolutionary pressure that drives AMR.”

Currently in preclinical development, Veirulence Ltd is developing a first-in-class non-antibiotic small molecule specifically targeting swarming, a key virulence factor of P. aeruginosa. “Virulence factor targeting therapies are a huge white space in drug development against bacteria. They are a distinct new drug class, which hit a key chokehold in the bacterial process,” explains Triniman.

Potentiation effects and patient impact

Using an ‘upstream blocker’ approach, this novel mechanism potentiates antibiotics, amplifying and extending their potential efficacy.1 Triniman envisions virulence factor targeting therapies being used alongside standard-of-care treatments to reduce the burden and rate of infection, improving patient outcomes and helping to preserve our arsenal of existing and future antibiotics.

Veirulence Ltd has developed a first-in-class non-antibiotic small molecule specifically targeting swarming

“This is a therapy area which has remained largely unchanged for decades,” says Triniman. “But just as immunotherapy transformed cancer treatment beyond chemotherapy, we believe targeting virulence factors has the potential to fundamentally change how we treat bacterial infections.”

Veirulence Ltd is building the evidence base needed to bring this novel therapeutic class into clinical practice. Its clinical potential is mirrored by its commercial potential, with opportunities to address bacterial infections and AMR beyond human medicine in veterinary and agriculture.

More from AMR & Infectious Diseases